Comparative analysis of long-term results of external beam and combined radiotherapy in high-risk prostate cancer patients
https://doi.org/10.18027/2224-5057-2020-10-3-26-33
Abstract
Prostate cancer (PCa) of high risk is one of the crucial problems in urological oncology. Radiation therapy (RT), along with radical prostatectomy, is an important component of the complex treatment of patients with high‑risk PCa. To improve the long‑term oncological results of RT dose escalation is advocated. Currently, dose escalation can be reached via external beam irradiation and interstitial RT techniques. The study included 109 patients with high‑risk PCa who underwent either external beam RT up to 76 Gy, or combined RT (external beam + interstitial RT) using 125I sources with long‑term androgen deprivation therapy. Comparative analysis of long‑term results of patients with high‑risk PCa treatment showed an improvement in 5‑year disease‑free survival rates after combined RT compared with external beam RT. Acute rectal toxicity was decreased in combined RT group compared to patients after external beam RT: 13.2 % and 46.4 %, respectively (p < 0.01).
About the Authors
A. V. Potapova
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Anna V. Potapova, Postgraduate Student
Moscow
I. A. Gladilina
N. N. Blokhin National Medical Research Center of Oncology; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Irina A. Gladilina, MD, PhD, DSc, Senior Researcher, Radiotherapy Department, N. N. Blokhin National Medical Research Center of Oncology, Professor Department of Oncology and Radiotherapy of Faculty of General Medicine, Pirogov Russian National Research Medical University
Moscow
A. V. Petrovsky
N. N. Blokhin National Medical Research Center of Oncology; I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Alexander V. Petrovsky, MD, PhD, Deputy Director for Education, N. N. Blokhin National Medical Research Center of Oncology, Associate Professor, Department of Oncology, Institute of Clinical Medicine, I. M. Sechenov First Moscow State Medical University
Moscow
L. E. Rotobelskaya
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Lidiya E. Rotobelskaya, Research Associate, Medical Cybernetics Group, Radiology Unit
Moscow
M. A. Shabanov
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Mikhail A. Shabanov, MD, PhD, DSc, Prof., Leading Research, Department of Human Pathological Anatomy
Moscow
V. A. Chernyaev
City Clinical Oncological Hospital № 1
Russian Federation
Russian Federation
Vitaliy A. Chernyaev, MD, PhD, Oncologist of the 2nd Oncology Department
Moscow
V. N. Sholokhov
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Vladimir N. Sholokhov, MD, PhD, DSc, Prof., Leading Research Associate, Ultrasonography Unit
Moscow
S. I. Tkachev
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Sergei I. Tkachev, MD, PhD, DSc, Prof., Leading Research Associate, Radiotherapy Department
Moscow
References
1. Dearnaley D. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial / Dearnaley D.P., Sydes M.R., Graham J.D., Aird E.G., et al. // Lancet Oncol. – 2007 – V. 8 (6) – P. 475–487.
2. Kuban D. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? / Kuban D.A., Levy L.B., Cheung M.R., Lee A.K., et al. // Int. J Radiat. Oncol. Biol. Phys. – 2011 – V. 79 (5) – P. 1310-1317.
3. Michalski J. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial / Michalski J.M., Moughan J., Purdy J., et al. // JAMA Oncol. – 2018 – V. 4 (6) – P. 180039.
4. Peeters S. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy / Peeters S.T., Heemsbergen W.D., Koper P.C., van Putten W.L., et al. // J Clin. Oncol. – 2006 – V. 24 (13) – V. 1990-1996.
5. Sathya J. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate / Sathya J.R., Davis I.R., Julian J.A., et al. // J Clin. Oncol. - 2005 – V. 23 (6) – P. 1192-1199.
6. Zietman A. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09 / Zietman A.L., Bae K., Slater J.D., Shipley W.U., et al. // J Clin. Oncol. – 2010 – V. 28 (7) – P. 1106-1111.
7. Shilkrut M. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer / Shilkrut M., Merrick G.S., McLaughlin P.W., et al. // Cancer – 2013 – V. 119 (3) – P. 681-690.
8. Taira A. Long-term outcomes of prostate cancer patients with Gleason pattern 5 treated with combined brachytherapy and external beam radiotherapy / Taira A.V., Merrick G.S., Galbreath R.W., et al. // Brachytherapy – 2013 – V. 12 (5) – P. 408-414.
9. Liss A. Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5 / Liss A.L., Abu-Isa E.I., Jawad M.S., et al. // Brachytherapy – 2015 – V. 14 (4) – P. 502-510
10. Hoskin P. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer / Hoskin P.J., Rojas A.M., Bownes P.J., et al. // Radiother. Oncol. – 2012 – V. 103 (2) – P. 217-222.
11. Morris W. Is ASCENDE-RT still pertinent? Is LDR-PB obsolete? / W. James Morris, Scott Tyldesley, Sree Rodda, Ross Halperin et al. // URL: https://www.prostatebrachytherapy.org.uk/2016-presentations/J-Morris%20170516.pdf – 2016
12. Morris W. Androgen suppression Combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate Brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer / Morris W.J., Tyldesley S., Rodda S., Halperin R., Pai H., McKenzie M., et al. // Int. J Radiat. Oncol. Biol. Phys. – 2017 – V. 98 (2) – P. 275-285.
13. Rodda S. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a LowDose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer / Rodda S., Tyldesley S., Morris W.J., Keyes M., et al. // Int. J Radiat. Oncol. Biol. Phys. – 2017 – V. 98 (2) – P. 286-295.
14. Chan E. Decline in acute urinary toxicity: A long-term study in 2011 patients with prostate brachytherapy within a provincial institution / Chan E.K., Keyes M., Pickles T., et al. // Brachytherapy – 2014 – V. 13 (1) – P. 46-52.
15. Cancer Stat Facts: Prostate Cancer. SEER, 2018. https://seer.cancer.gov/statfacts/html/prost.html.
16. Draisma G. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context / Draisma G., Etzioni R., Tsodikov A., Mariotto A., Wever E., Gulati R., Feuer E. // J. Natl. Cancer Inst. – 2009 – V. 101 (6) – P. 374-383.
17. Bolla M. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study / Michel Bolla, Geertjan Van Tienhoven, Padraig Warde et al. // Lancet Oncol. – 2010 – V. 11 (11) – P. 1066–1073.
18. EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona 2019. ISBN 978-94-92671-04-2.
19. Pilepich M. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31 / Pilepich M.V., Winter K., Lawton C.A., Krisch R.E., et al. // Int. J Radiat. Oncol. Biol. Phys. – 2005 – V. 61 (5) – P. 1285-1290.
20. Vogelius I. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: Bad news, good news, or no news? / Vogelius I.R., Bentzen S.M. // Int. J Radiat. Oncol. Biol. Phys. – 2013 – V. 85 (1) – P. 89-94.
Review
For citations:
Potapova A.V., Gladilina I.A., Petrovsky A.V., Rotobelskaya L.E., Shabanov M.A., Chernyaev V.A., Sholokhov V.N., Tkachev S.I. Comparative analysis of long-term results of external beam and combined radiotherapy in high-risk prostate cancer patients. Malignant tumours. 2020;10(3):26-33. (In Russ.) https://doi.org/10.18027/2224-5057-2020-10-3-26-33
Views:
644
Email this article 